MLYS Stock Overview
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Mineralys Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.87 |
| 52 Week High | US$17.70 |
| 52 Week Low | US$5.85 |
| Beta | 0 |
| 1 Month Change | -8.06% |
| 3 Month Change | 8.50% |
| 1 Year Change | -11.75% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -35.63% |
Recent News & Updates
Mineralys Therapeutics: A Story To Keep An Eye On
Mar 18Mineralys: 2nd Half 2024 Hypertension Data Readout
Feb 09Recent updates
Shareholder Returns
| MLYS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 5.1% | -0.2% | 2.9% |
| 1Y | -11.7% | -1.0% | 22.2% |
Return vs Industry: MLYS underperformed the US Biotechs industry which returned 0.9% over the past year.
Return vs Market: MLYS underperformed the US Market which returned 21.9% over the past year.
Price Volatility
| MLYS volatility | |
|---|---|
| MLYS Average Weekly Movement | 9.3% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MLYS's share price has been volatile over the past 3 months.
Volatility Over Time: MLYS's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | 28 | Jon Congleton | mineralystx.com |
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020.
Mineralys Therapeutics, Inc. Fundamentals Summary
| MLYS fundamental statistics | |
|---|---|
| Market cap | US$589.12m |
| Earnings (TTM) | -US$71.90m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.2x
P/E RatioIs MLYS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MLYS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$71.90m |
| Earnings | -US$71.90m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.45 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MLYS perform over the long term?
See historical performance and comparison